Clinical Trials Directory

Trials / Sponsors / Immatics Biotechnologies GmbH

Immatics Biotechnologies GmbH

Industry · 7 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
RecruitingIMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
Phase 1 / Phase 22023-08-09
Active Not RecruitingIMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
Phase 12022-05-19
CompletedGAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Glioblastoma
Phase 12014-10-01
TerminatedPeptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
Glioblastoma
Phase 12011-08-01
CompletedIMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Phase 32010-12-01
CompletedIMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Foll
Colorectal Carcinoma
Phase 1 / Phase 22008-06-01
CompletedIMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease
Renal Cell Carcinoma
Phase 22007-05-01